In a groundbreaking recommendation, the National Comprehensive Cancer Network (NCCN) has broadened the scope of prostate cancers that qualify for active surveillance in the United States to include ...

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic ...

Why would any healthy person, newly diagnosed with cancer, elect not to undergo curative treatment? Newly diagnosed prostate cancer patients presented with the option of active surveillance often ask ...

WEDNESDAY, Aug. 6, 2025 (HealthDay News) -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online July ...

Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

Please provide your email address to receive an email when new articles are posted on . Many men with prostate cancer received excessive treatment because of broad risk guidelines. AI can help ...

SAN FRANCISCO -- Prophylactic whole-pelvic radiation therapy (RT) did not perform as expected for patients with unfavorable intermediate-risk or favorable high-risk prostate cancer, according to ...